Annexon (NASDAQ:ANNX) Issues Quarterly Earnings Results

Annexon (NASDAQ:ANNX) issued its quarterly earnings data on Monday. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05), Zacks reports.

Annexon Price Performance

ANNX opened at $2.39 on Tuesday. The business has a fifty day simple moving average of $3.96 and a 200 day simple moving average of $5.42. The company has a market capitalization of $254.76 million, a PE ratio of -2.28 and a beta of 1.07. Annexon has a 1 year low of $2.39 and a 1 year high of $8.40.

Analysts Set New Price Targets

Several analysts have recently commented on ANNX shares. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Annexon in a research note on Tuesday, December 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Annexon in a research note on Friday, November 15th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $15.80.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.